Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Convertible Debt (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Convertible Debt data on record, last reported at $93.5 million in Q2 2025.

  • For Q2 2025, Convertible Debt changed 0.34% year-over-year to $93.5 million; the TTM value through Jun 2025 reached $93.5 million, changed 0.34%, while the annual FY2024 figure was $93.3 million, 0.33% changed from the prior year.
  • Convertible Debt reached $93.5 million in Q2 2025 per APLS's latest filing, roughly flat from $93.4 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $386.5 million in Q2 2021 and bottomed at $92.7 million in Q3 2022.
  • Average Convertible Debt over 5 years is $147.0 million, with a median of $93.3 million recorded in 2024.
  • Peak YoY movement for Convertible Debt: skyrocketed 167.12% in 2021, then tumbled 51.13% in 2022.
  • A 5-year view of Convertible Debt shows it stood at $189.0 million in 2021, then tumbled by 50.94% to $92.7 million in 2022, then rose by 0.32% to $93.0 million in 2023, then grew by 0.33% to $93.3 million in 2024, then increased by 0.17% to $93.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Convertible Debt were $93.5 million in Q2 2025, $93.4 million in Q1 2025, and $93.3 million in Q4 2024.